Date: 2016-03-17
Type of information: Nomination
Compound:
Company: Kymab (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 17, 2016, Kymab, the Cambridge-based antibodies-tomedicines company, announced the appointment of Dr David Chiswell OBE as Chief Executive Officer with effect from April 2016. Dr Chiswell has occupied the position as Kymab interim CEO since early 2015 having been appointed Chairman in September 2013. Dr Chiswell will step down from his role as Chairman and Dr Tim Rink will take the role of Lead Director with effect from April.
Dr Chiswell has over 30 years’ experience in the biotechnology industry having cofounded Cambridge Antibody Technology (CAT) in 1990, serving as CEO from 1996 to 2002. CAT listed on the London Stock exchange in April 1997 and Nasdaq in June 2001, and was subsequently sold to AstraZenca where it forms an important part of its
biopharmaceutical franchise. Since leaving CAT in 2002, he has focused on the development of early-stage biotechnology companies, having previously served as a director of Arakis, non-executive chairman of Sosei, Arrow Therapeutics and Daniolabs, and as CEO of Nabriva Therapeutics (2009 to 2012). Dr Chiswell currently serves as
chairman of Albireo Pharma and is a director of Nabriva Therapeutics. He is a past chairman of the UK BioIndustry association (BIA) and in 2006 he was awarded the Most Excellent Order of the British Empire (OBE) by Her Majesty the Queen for services to the biotechnology industry.
Financial terms:
Latest news:
